Loading
A phase 3 trial of Durvalumab, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT03800134 by AstraZeneca, with 825 participants enrolled, started 2018-12-06 and due to reach its primary completion in 2022-11-10. Interventions recorded: Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Durvalumab, Paclitaxel / nab-paclitaxel.
Shares Pemetrexed, Durvalumab, Paclitaxel / nab-paclitaxel, Gemcitabine.
Shares Durvalumab, Paclitaxel / nab-paclitaxel, Gemcitabine, AstraZeneca.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, AstraZeneca, Cisplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Gemcitabine, Cisplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin.